Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/9/2026

1. SPY
2. USO
3. META
4. MSFT
5. MU
6. COST
7. IONS
8. CME
9. AVAV
10. SKHY

Go back to Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

July 26, 2024 6:50 AM EDT

Opinion granted based on positive overall survival and progression-free survival results from the Phase 3 KEYNOTE-A39 trial

Positive opinion marks step forward for a potential new first-line standard of care for the treatment of patients with this disease in... More